[{"orgOrder":0,"company":"PanTheryx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Bifidobacterium","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PanTheryx \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ Inapplicable"},{"orgOrder":0,"company":"PanTheryx","sponsor":"PanTheryx","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Goodgut","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"PanTheryx","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PanTheryx \/ PanTheryx","highestDevelopmentStatusID":"15","companyTruncated":"PanTheryx \/ PanTheryx"}]

Find Clinical Drug Pipeline Developments & Deals by PanTheryx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Kids Chewable probiotic supplements, TruBiotics (Bifidobacterium) and Lactobacillus launched by company, the two most-clinically researched probiotic types to support digestive and immune heath for children.

                          Product Name : TruBiotics

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          February 03, 2022

                          Lead Product(s) : Bifidobacterium,Lactobacillus Rhamnosus

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The acquisition adds a high-quality prebiotic to the PanTheryx product lines that already include bovine colostrum for digestive and immune human health.

                          Product Name : Goodgut

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Undisclosed

                          October 14, 2020

                          Lead Product(s) : Goodgut,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Recipient : Greenteaspoon

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 04, 2017

                          Lead Product(s) : E1392-75-2A,PTM202

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Recipient : NIZO Food Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          March 11, 2015

                          Lead Product(s) : PTM202,Inapplicable

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Recipient : University of Colorado, Denver

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank